Zusammenfassung
Das kutane Melanom ist der Hauttumor mit der höchsten Metastasierungsrate und zählt zu den häufigsten soliden Tumoren. Die Inzidenz ist steigend. Nachdem die Therapieoptionen jahrelang stark limitiert waren, eröffnen sich dank des Forschungsfortschritts der letzten Jahre neue Optionen für zielgerichtete oder immunmodulatorische Therapien für Patienten im fortgeschrittenen Tumorstadium. Die neue S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms, veröffentlicht im Januar dieses Jahres, bietet eine Entscheidungshilfe für dermatologisch und onkologisch tätige Ärzte in Praxis und Klinik. Ziel ist es, Qualitätsstandards zu setzen und damit langfristig die Versorgung von Melanompatienten verbessern.
Literatur
Bafounta ML, Beauchet A, Aegerter P et al (2001) Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch Dermatol 137:1343–1350
Kittler H, Pehamberger H, Wolff K et al (2002) Diagnostic accuracy of dermoscopy. Lancet Oncol 3:159–165
Tronnier M, Garbe C, Brocker EB et al (1997) Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society. Hautarzt 48:720–729
Pflugfelder A, Weide B, Eigentler TK et al (2010) Incisional biopsy and melanoma prognosis: facts and controversies. Clin Dermatol 28:316–318
Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206
Valsecchi ME, Silbermins D, Rosa N de et al (2011) Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol
Warycha MA, Zakrzewski J, Ni Q et al (2009) Meta-analysis of sentinel lymph node positivity in thin melanoma (< or=1 mm). Cancer 115:869–879
McMasters KM, Wong SL, Edwards MJ et al (2001) Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 130:151–156
Bafounta ML, Beauchet A, Chagnon S et al (2004) Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol 5:673–680
Brand CU, Ellwanger U, Stroebel W et al (1997) Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 79:2345–2353
Sanki A, Scolyer RA, Thompson JF (2009) Surgery for melanoma metastases of the gastrointestinal tract: indications and results. Eur J Surg Oncol 35:313–319
Yancovitz M, Finelt N, Warycha MA et al (2007) Role of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanoma. Cancer 110:1107–1114
Vereecken P, Laporte M, Petein M et al (2005) Evaluation of extensive initial staging procedure in intermediate/high-risk melanoma patients. J Eur Acad Dermatol Venereol 19:66–73
Xing Y, Bronstein Y, Ross MI et al (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 19(103):129–142
Sawyer A, McGoldrick RB, Mackey SP et al (2009)Does staging computered tomography change management in thick malignant melanoma? J Plast Reconstr Aesthet Surg 62:453–456
Tsao H, Feldman M, Fullerton JE et al (2004) Early detection of asymptomatic pulmonary melanoma metastases by routine chest radiographs is not associated with improved survival. Arch Dermatol 140:67–70
Hofmann U, Szedlak M, Rittgen W et al (2002) Primary staging and follow-up in melanoma patients-monocenter evaluation of methods, costs and patient survival. Br J Cancer 87:151–157
Mocellin S, Zavagno G, Nitti D (2008) The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 123:2370–2376
Kleeberg UR, Tews JT, Ruprecht T et al (2005) Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 13:303–310
Fallowfield L, Jenkins V, Farewell V et al (2002) Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial. Lancet 359:650–656
Gysels M, Richardson A, Higginson IJ (2004) Communication training for health professionals who care for patients with cancer: a systematic review of effectiveness. Support Care Cancer 12:692–700
Lehmann C, Koch U, Mehnert A (2009) Impact of the doctor-patient-communication on distress and utilization of psychosocial services among cancer patients. A review of the current literature. Psychother Psychosom Med Psychol 59:e3–e27
Sladden MJ, Balch C, Barzilai DA et al (2009) Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev 4:CD004835
Pflugfelder A, Kochs C, Garbe C et al (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms. http://www.leitlinienprogramm-onkologie.de/Leitlinien.7.0.html
Loser C, Rompel R, Breuninger H et al (2010) Microscopically controlled surgery (MCS). J Dtsch Dermatol Ges 8:920–925
Lichte V, Breuninger H, Metzler G et al (2009) Acral lentiginous melanoma: conventional histology vs. three-dimensional histology. Br J Dermatol 160:591–599
Weide B, Derhovanessian E, Pflugfelder A et al (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116:4139–4146
Moreno-Ramirez D, Cruz-Merino L, Ferrandiz L et al (2010) Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist 15:416–427
Burmeister BH, Henderson MA, Ainslie J et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 13:589–597
Garbe C, Eigentler TK, Keilholz U et al (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5–24
Mocellin S, Pasquali S, Rossi CR et al (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102:493–501
Leo F, Cagini L, Rocmans P et al (2000) Lung metastases from melanoma: when is surgical treatment warranted? Br J Cancer 83:569–572
Avril MF, Aamdal S, Grob JJ et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125
Middleton MR, Grob JJ, Aaronson N et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
Patel PM, Suciu S, Mortier L et al (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47:1476–1483
Eigentler TK, Caroli UM, Radny P et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759
Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516
Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526
Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607–618
Romano E, Scordo M, Dusza SW et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28:3042–3047
Author information
Authors and Affiliations
Corresponding author
Additional information
Die Autoren C. Kochs und A. Pflugfelder haben gleichermaßen zum Artikel beigetragen.
Interessenkonflikt
Es wird auf folgende Beziehungen hingewiesen: A. Pflugfelder hat ein Beraterhonorar der Firma Bristol-Myers Squibb erhalten. D. Schadendorf: Beratungstätigkeiten und Vorträge für Roche, GSK, BMS, Amgen, MSD; Beratungstätigkeiten für Novartis; Reisekostenübernahme von Roche, BMS.
Rights and permissions
About this article
Cite this article
Kochs, D.C., Pflugfelder, A., Garbe, C. et al. Die neue S3-Leitlinie „Melanom“. best practice onkologie 8, 40–48 (2013). https://doi.org/10.1007/s11654-013-0044-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11654-013-0044-2